Trial · NCT02563574
ARCH II Study (Alcohol Research Center on HIV Study II)
NCT02563574, Not applicable, Completed, University of Florida
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. ARCH II Study (Alcohol Research Center on HIV Study II). Trials, record NCT02563574. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02563574
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ARCH II Study (Alcohol Research Center on HIV Study II)
- NCT number
- NCT02563574
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 14 participants, actual
- Lead sponsor
- University of Florida
- Conditions
- Alcohol Consumption, HIV, Motivation
- Interventions
- Motivational Interviewing, Questionnaire assessment, Neurocognitive assessments, Blood specimens
- First posted
- 2015-09-30
- Last updated
- 2022-04-04
Source ClinicalTrials.gov
Registered outcomes29
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | FMRI images will be performed for changes in the brain between the groups | Baseline and 6 month follow-up | Cerebral metabolite abnormalities |
| Secondary | Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)-IV (SCID) | Baseline | A structured interview given to participants in order to assess current and past alcohol use and dependence |
| Secondary | Lifetime Alcohol and Drug Use History | Baseline | This interview will be conducted at baseline to gather information about age of onset of alcohol use, period of heaviest drinking, most drinks consumed on a single day, and number of drug classes used lifetime. |
| Secondary | Kreek-McHugh-Schluger-Kellogg (KMSK) Scale | Baseline, 3-month, 6-month, and 12-month follow-ups. | Developed as a research measure of drug use severity in accordance with DSM-IV criteria, the KMSK is reliable and valid, quantifying frequency, duration, and amount of individual drug use. |
| Secondary | Timeline Followback (TLFB) | Baseline, 3-month, 6-month, and 12-month follow-ups. | The TLFB interview will be used to assess recent alcohol use at baseline, as well as during the follow-up intervals. The TLFB interview is a calendar-assisted structured interview which provides a way to cue memory so that accurate recall is enhanced. The TLFB will provide data on the percentage of drinking days, drinks consumed per week, and the percentage of heavy drinking days. |
| Secondary | Urine Drug Screen | Baseline, 3-month, 6-month, and 12-month follow-ups. | Urine drug screens will be performed using Varian's TestCup Pro5, testing for benzodiazepines, amphetamines, opiates, \& cocaine. |
| Secondary | Short Inventory of Problems (SIP) | Baseline, 3-month, 6-month, and 12-month follow-ups. | The SIP assesses 15 negative consequences of alcohol use over the chosen time period (in this case 3 months) and has been found to have good psychometric properties. Maximum score is 45 |
| Secondary | Epworth Sleepiness Scale (ESS) | Baseline, 3-month, 6-month, and 12-month follow-ups. | The ESS proposes eight daytime scenarios, and the participant is asked to rate how likely they are to fall asleep in each situation on a four-point scale (0-3). |
| Secondary | Center for Epidemiological Studies-Depression Scale (CES-D) | Baseline, 3-month, 6-month, and 12-month follow-ups. | A 20-item screening test for depression and depressive disorder |
| Secondary | Beck Anxiety Inventory | Baseline, 3-month, 6-month, and 12-month follow-ups. | 21-question multiple-choice self-report inventory that is used for measuring the severity of anxiety |
1 to 10 of 29Source ClinicalTrials.gov
See all 29 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 37039068 | DERIVED |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P01AA019072 | Addressing alcohol misuse in HIV prevention and care: The Brown University Alcohol Research Center on HIV (ARCH) | KAHLER, CHRISTOPHER W. | BROWN UNIVERSITY | NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM | 2010 to 2024 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests10
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Category Fluency | Secondary outcome | ConductCognition |
| Continuous Performance Test | Secondary outcome | ConductCognition |
| Letter-Number Sequencing Task | Secondary outcome | ConductCognition |
| Paced Visual Serial Addition Test | Secondary outcome | ConductCognition |
| Picture Naming Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Symbol Scan Task | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02563574
GET https://conductscience.org/api/trials/v1/NCT02563574/registered?page=2